PT  - JOURNAL ARTICLE
AU  - Leung, Peter Q.
AU  - Elghonaimy, Eslam A.
AU  - Elamir, Ahmed M.
AU  - Wachsmann, Megan
AU  - Zhang, Song
AU  - Barrows, Neha
AU  - Notgrass, Hollis
AU  - Johnson, Ethan
AU  - Lewis, Cheryl
AU  - von Ebers, Rachel
AU  - Hamilton, Cassandra
AU  - Josephson, Grace
AU  - Chi, Zhikai
AU  - Al Mutar, Salwan
AU  - Polanco, Patricio M.
AU  - Sanford, Nina N.
AU  - Ali Kazmi, Syed M.
AU  - Porembka, Matthew R.
AU  - Hsiehchen, David
AU  - Yopp, Adam C.
AU  - Mansour, John
AU  - Beg, Muhammad S.
AU  - Zeh, Herbert J.
AU  - Aguilera, Todd A.
TI  - Presurgical ablative radiation associates with local control and immune response in pancreatic cancer
AID  - 10.1101/2024.11.11.24317120
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.11.11.24317120
4099  - http://medrxiv.org/content/early/2024/11/11/2024.11.11.24317120.short
4100  - http://medrxiv.org/content/early/2024/11/11/2024.11.11.24317120.full
AB  - Purpose To compare outcomes and molecular characteristics of patients who had surgery after neoadjuvant chemotherapy, with and without ablative radiotherapy (SAbR) for pancreas cancer.Experimental Design This single-institution, tertiary care academic center cohort study included all patients diagnosed with pancreatic cancer between 2012-2023 treated with neoadjuvant chemotherapy, with or without SAbR. We compared therapeutic responses, performed cardinality matching with distance-optimized pairing, and conducted multivariable stepwise-AIC-optimized Cox modeling to identify differences between groups. We assessed molecular response using RNA sequencing to identify SAbR-induced biologic differences.Results Among 133 patients receiving chemotherapy and 48 chemotherapy + SAbR, RNA sequencing was available for 29 and 14 patients, respectively. Despite more advanced baseline disease, the SAbR group showed better post-treatment pathology and similar overall survival (HR = 0.97, 95% CI = 0.58–1.60, P = .9). Patient matching indicated that SAbR improved locoregional recurrence-free survival (HR = 0.24, 95% CI = 0.07–0.88, P = .009). Arterial involvement raised local failure risk with chemotherapy alone (HR = 3.37, 95% CI = 1.74–6.54, P < .001), which was significantly reduced with SAbR (HR = 0.28; 95% CI = 0.12–0.68; P = .003). Gene set enrichment analysis showed immune activation, with CD8 and NK/NKT cell signatures associated with local control, and Treg signatures associated with worse control.Conclusion Neoadjuvant SAbR resulted in improved pathological outcomes, enhanced local control, and maintained survival while inducing a distinct immune response. The role of neoadjuvant SAbR should be further evaluated in well powered studies to define clinical benefits.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research work is supported by the CPRIT Recruitment of First-Time, Tenure-Track Faculty Members RR170051 and the UTSW SCCC Translational Cancer Research Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the University of Texas Southwestern gave ethical approval for this work. All procedures were conducted under IRB-approved protocol STU 072018-037. Patient consents for tissue collection were performed under IRB- approved protocol STU 102010-098.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes